Choosing the right cell line for rectal cancer research
Metadatos
Afficher la notice complèteAuteur
Moya Ramírez, Miguel Ángel; Sánchez Martín, Victoria; Herrera Merchán, Antonio; Medina Vico, Pedro Pablo; Cuadros Celorrio, Marta EugeniaEditorial
Archivos de Medicina Universitaria
Materia
C-MYC Rectal tumor Response Cell line
Date
2015Referencia bibliográfica
Moya Ramírez, Miguel Ángel; Sánchez Martín, Victoria; Herrera Merchán, Antonio; Medina Vico, Pedro Pablo; Cuadros Celorrio, Marta Eugenia. Choosing the right cell line for rectal cancer research. AMU. 2015; 3: 17-20
Résumé
Up to date no effective method exists that predicts
response to preoperative chemoradiation (CRT) in
locally advanced rectal cancer (LARC). Nevertheless,
identification of patients who have a higher likelihood
of responding to preoperative CRT could be crucial in
decreasing treatment morbidity and avoiding expensive
and time-consuming treatments. Using the Gng4, c-Myc,
Pola1, and Rrm1 signature, we were able to establish
a model to predict response to CRT in rectal cancer
with a sensitivity of 60% and 100% specificity. The aim
of this study was to characterize c-Myc status in DNA,
RNA and protein levels in 3 tumoral cell lines (SW480,
SW620 and SW837) to establish the best cell line model
and, subsequently, carry out genome silencing of
c-Myc by means of RNA interference (iRNA). To study
the expression levels of c-Myc, we used Polymerase
Chain Reaction (PCR) amplifications and sequencing;
quantitative real time PCR (qRT-PCR); and western blot
analysis in each cell line. SW480 and SW620 showed a
variation A > G in exon 2, which caused a substitution
of aspargine to serine, and SW837 revealed a G > A
transition in the same, which caused a mutation at
codon 92. The three cell lines expressed c-Myc mRNA.
SW837 showed a decrease of c-Myc expression levels
compared with SW480, and SW620. At protein level,
SW620 showed the highest expression of c-Myc.
According to the results obtained, we can perform
c-Myc gene silencing experiments to analyze the
role of this biomarker in response to treatment.